Propanc Biopharma, Inc. — fact timeline

Propanc Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 31, 2025, Propanc Biopharma, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “ Bid Price Requirement ”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bi”

Propanc Biopharma, Inc. issued up to an additional 9,900 shares of Series C Preferred Stock of warrant to Hexstone Capital LLC for cash payment of $1,000,099.00.

“a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock, at an exercise price of $10,000 per Warrant share in exchange for cash payment of $1,000,099.00 to the Company.”

Propanc Biopharma, Inc. issued 100 shares of Series C Preferred Stock of preferred stock to Hexstone Capital LLC for cash payment of $1,000,099.00.

“Hexstone purchased 100 shares of Series C Preferred Stock of the Company and a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock, at an exercise price of $10,000 per Warrant share in exchange for cash payment of $1,000,099.00 to the Company.”

Propanc Biopharma, Inc.: Filed Certificate of Designation creating Series C Preferred Stock as an amendment to the Certificate of Incorporation (effective 2025-11-04).

“On November 4, 2025, the Company amended its Certificate of Incorporation and filed a Certificate of Designation with the Delaware Secretary of State that authorized the issuance of up to 9,900 shares of a new series of preferred stock, par value $0.01 per share, designated as “Series C Preferred Stock” for which the Board established the rights, preferences and limitations thereof.”

Propanc Biopharma, Inc. incurred convertible notes of $112,350 at 22% per annum maturing April 30, 2026.

“Effective July 25, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $112,350 (the “Note”)”

Propanc Biopharma, Inc. incurred convertible notes of $82,500 with an accredited investor at 10% per annum maturing September 15, 2025.

“Effective July 18, 2025, Propanc Biopharma, Inc. (the “Company”) issued a Promissory Note to an accredited investor (the “Investor”) in the aggregate principal amount of 82,500 (the “Note”), for a purchase price of $75,000.”

Propanc Biopharma, Inc. incurred convertible notes of $67,860.00 with an investor at one-time interest charge of fifteen percent (15%) maturing April 16, 2026.

“with an investor (the “Investor”) pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $67,860.00 (the “Note”), for a purchase price of $58,000. The Company intends to use the net proceeds therefrom for general working capital purposes. The maturity date of the Note is April”

Propanc Biopharma, Inc. incurred loan of $13,188 AUD with one of our members of the Board of Directors (the “Board Member”) at 12% per annum maturing June 30, 2025.

“Effective Junel 13, 2025, the Company entered into and closed a loan agreement (the “Loan”) with one of our members of the Board of Directors (the “Board Member”), pursuant to which the Board Member loaned the Company an aggregate principal amount of $13,188 AUD.”

Propanc Biopharma, Inc. incurred convertible notes of $25,000 with an investor at 8% per annum maturing June 12, 2026.

“Effective June 12, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $25,000 (the “Note”), for a purchase price of $22,500.”

Propanc Biopharma, Inc. incurred loan of $60,000 with an accredited investor at ten percent (10%) per annum maturing July 15, 2025.

“Effective June 2, 2025, Propanc Biopharma, Inc. (the “Company”) issued a Promissory Note to an accredited investor (the “Investor”) in the aggregate principal amount of $60,000 (the “Note”), for a purchase price of $50,000.”

Propanc Biopharma, Inc. amended loan of not changed with same Investor at not changed maturing June 15, 2025 (extended from previous maturity; Note dated August 15, 2023, previously amended May 7, 2024).

“Effective May 7, 2025, the Company entered into a Maturity Extension Agreement (the "Extension Agreement") with the same Investor whereby the Investor agreed to extend the maturity date of a previously issued promissory note dated August 15, 2023, which was amended on May 7, 2024 (the "Old Note") to June 15, 2025.”

Propanc Biopharma, Inc. incurred loan of aggregate principal amount of $90,000, for a purchase price of $75,000 with accredited investor at ten percent (10%) per annum maturing June 15, 2025.

“Effective May 7, 2025, Propanc Biopharma, Inc. (the "Company") issued a Promissory Note to an accredited investor (the "Investor") in the aggregate principal amount of $90,000 (the "Note"), for a purchase price of $75,000.”

Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $79,200 with an investor at one-time interest charge of fifteen percent (15%) maturing January 30, 2026.

“Effective March 31, 2025, the Company entered into and closed a securities purchase agreement (“Purchase Agreement 2”) with an investor (the “Investor 2”), pursuant to which Investor 2 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $79,200 (“Note 2”), for a purchase price of $67,000.”

Propanc Biopharma, Inc. incurred loan of aggregate principal amount of $63,188 AUD with one of our members of the Board of Directors at twelve percent (12%) per annum maturing June 30, 2025.

“Effective April 13, 2025, the Company entered into and closed a loan agreement (the “Loan”) with one of our members of the Board of Directors (the “Board Member”), pursuant to which the Board Member loaned the Company an aggregate principal amount of $63,188 AUD.”

Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $55,000 with an investor at eight percent (8%) per annum maturing December 15, 2025.

“Effective April 15, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (“Purchase Agreement 1”) with an investor (“Investor 1”), pursuant to which Investor 1 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $55,000 (“Note 1”), for a purchase price of $50,000.”

Propanc Biopharma, Inc. incurred convertible notes of $43,000 at eight percent (8%) per annum maturing October 7, 2025.

“the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $43,000”

Propanc Biopharma, Inc. incurred convertible notes of $65,000 at one-time interest charge of fifteen percent (15%) maturing November 30, 2025.

“the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $65,000”

Propanc Biopharma, Inc. entered into Maturity Extension Agreement with Ionic Ventures, LLC (effective 2024-05-10).

“On May 10, 2024, Propanc Biopharma, Inc. (the “Company”) entered into a Maturity Extension Agreement (the “Extension Agreement”) with Ionic Ventures, LLC (the “Ionic”), pursuant to which the Ionic agreed to extend the maturity date of original 10% OID Promissory Note issued on August 15, 2023 (the “Original Note”) to September 30, 2024.”

Propanc Biopharma, Inc. incurred convertible notes of $27,500 with an investor at eight percent (8%) per annum maturing October 12, 2024.

“Effective April 16, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $27,500 (the “Note”), for a purchase price of $25,000.”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “Investor”) valued at aggregate principal amount of $27,500 (effective 2024-04-16).

“Effective April 16, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $27,500 (the “Note”), for a purchase price of $25,000.”

Propanc Biopharma, Inc. incurred convertible notes of $50,000 with an investor at eight percent (8%) per annum, which may be increased to sixteen percent (16%) in maturing March 1, 2024.

“Effective March 5, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000 (the “Note”), for a purchase price of $46,875.”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at $50,000 (effective 2024-03-05).

“Effective March 5, 2024, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $50,000”

Propanc Biopharma, Inc. incurred convertible notes of $150,000 with Investor at ten percent (10%) per annum maturing December 8, 2024.

“entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $150,000”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at principal amount of $150,000 (effective 2023-12-11).

“Effective December 11, 2023, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $150,000 (the “Note”), for a purchase price of $135,000.”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at $45,000 (effective 2023-12-04).

“Effective December 4, 2023, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $45,000 (the “Note”), for a purchase price of $45,000.”

Propanc Biopharma, Inc. incurred convertible notes of $40,000 with an investor at 8% per annum, which may be increased to 22% in the event of a default maturing October 20, 2024.

“On October 20, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $40,000”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the "Investor") valued at $40,000 (effective 2023-10-20).

“On October 20, 2023, Propanc Biopharma, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with an investor (the "Investor"), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $40,000 (the "Note")”

Propanc Biopharma, Inc. incurred convertible notes of $61,000 with an investor at 8% per annum maturing April 12, 2024.

“On October 12, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible redeemable promissory note from the Company in the aggregate principal amount of $61,000 (the “Note”)”

Propanc Biopharma, Inc. entered into Purchase Agreement with Investor valued at $61,000 (effective 2023-10-12).

“On October 12, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible redeemable promissory note from the Company in the aggregate principal amount of $61,000 (the “Note”), for a purchase price of $57,500.”

Propanc Biopharma, Inc. incurred convertible notes of $77,500 with an investor at 8% per annum maturing February 23, 2024.

“On August 23, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on August 23, 2023, pursuant to which the Investor purchased a convertible redeemable promissory note in the aggregate principal amount of $77,500 (the “Note”) from the Company for $72,500.”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “Investor”) valued at $77,500 (effective 2023-08-23).

“On August 23, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on August 23, 2023, pursuant to which the Investor purchased a convertible redeemable promissory note in the aggregate principal amount of $77,500”

Propanc Biopharma, Inc. incurred loan of principal face amount of $132,000 with August Lender at 10% per annum, which may be increased to 18% in the event of a default maturing November 15, 2023.

“On August 15, 2023, the Company issued to an institutional investor (the “August Lender”) a 10% original issue discount promissory note (the “Promissory Note”) in consideration for $120,000, which has a principal face amount of $132,000, matures on November 15, 2023 and accrues interest at a rate of 10% per annum, which may be increased to 18% in the event of a default.”

Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $55,000 with August Investor at 8% per annum, which may be increased to 22% in the event of a default maturing August 16, 2024.

“On August 16, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “August Investor”), which closed on August 16, 2023, pursuant to which the August Investor purchased a convertible promissory note (the “August Note”) from the Company in the aggregate principal amount of $55,000”

Propanc Biopharma, Inc. entered into Promissory Note with an institutional investor (the “August Lender”) valued at $132,000 (effective 2023-08-15).

“On August 15, 2023, the Company issued to an institutional investor (the “August Lender”) a 10% original issue discount promissory note (the “Promissory Note”) in consideration for $120,000, which has a principal face amount of $132,000”

Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “August Investor”) valued at $55,000 (effective 2023-08-16).

“On August 16, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “August Investor”), which closed on August 16, 2023, pursuant to which the August Investor purchased a convertible promissory note (the “August Note”) from the Company in the aggregate principal amount of $55,000”

Propanc Biopharma, Inc. incurred convertible notes of $45,000 with an investor at 8% per annum, which may be increased to 22% in the event of a default maturing July 19, 2024.

“On July 19, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on July 28, 2023, pursuant to which the Investor purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $45,000”

Propanc Biopharma, Inc. terminated Equity Line Agreement (effective 2023-07-25).

“On July 25, 2023, due to a disagreement between the parties relating to the registration of such shares of Common Stock, the Company notified such investor of the termination of the Equity Line Agreement.”

Propanc Biopharma, Inc. entered into Purchase Agreement valued at $45,000 (effective 2023-07-19).

“On July 19, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on July 28, 2023, pursuant to which the Investor purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $45,000”

Propanc Biopharma, Inc. entered into common stock purchase agreement with an institutional investor valued at up to $5,000,000 (effective 2023-07-20).

“On July 20, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a common stock purchase agreement (the “Equity Line Agreement”) with an institutional investor (the “Investor”) providing for an equity financing facility, pursuant to which Company has the option to request that the Investor commit to purchase up to $5,000,000 of the Company’s shares”

Propanc Biopharma, Inc. incurred loan of AU$230,000 with July Investor at 10% maturing July 5, 2026.

“On July 5, 2023, the Company and an institutional investor (the “July Investor”) entered into a letter agreement (the “Loan Agreement”), pursuant to which the July Investor loaned the Company an aggregate of AU$230,000”

Propanc Biopharma, Inc. incurred convertible notes of $65,000 with June Investor at 8% per annum maturing June 29, 2024.

“On June 29, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “June Investor”), which closed on July 6, 2023, pursuant to which the June Investor purchased a convertible promissory note (the “June Note”) from the Company in the aggregate principal amount of $65,000”

Propanc Biopharma, Inc. entered into Loan Agreement with July Investor valued at AU$230,000 (effective 2023-07-05).

“On July 5, 2023, the Company and an institutional investor (the “July Investor”) entered into a letter agreement (the “Loan Agreement”), pursuant to which the July Investor loaned the Company an aggregate of AU$230,000.”

Propanc Biopharma, Inc. entered into Purchase Agreement with June Investor valued at $65,000 (effective 2023-06-29).

“On June 29, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “June Investor”), which closed on July 6, 2023, pursuant to which the June Investor purchased a convertible promissory note (the “June Note”) from the Company in the aggregate principal amount of $65,000”

Propanc Biopharma, Inc. reported a default on convertible notes.

“As of March 24, 2023, the Company was in default under the Note for failure to pay the initial and subsequent monthly payments of principal and accrued interest”

Propanc Biopharma, Inc. incurred convertible notes of $125,000 at 10% per annum maturing October 24, 2023.

“the Company issued the Investor a 10% unsecured convertible promissory note, dated November 3, 2022, with an aggregate face value of $125,000”

Propanc Biopharma, Inc. entered into Purchase Agreement with the Investor valued at $125,000 (effective 2022-11-03).

“entered into a note purchase agreement (the “Purchase Agreement”), pursuant to which the Company issued the Investor a 10% unsecured convertible promissory note, dated November 3, 2022, with an aggregate face value of $125,000”

Propanc Biopharma, Inc. entered into Equity Line Agreement with an institutional investor (the “Investor”) valued at $5,000,000 (effective 2022-11-03).

“entered into a stock purchase agreement (the “Equity Line Agreement”) with an institutional investor (the “Investor”) providing for an equity financing facility, pursuant to which Company has the option to request that the Investor commit to purchase up to $5,000,000 of the Company’s shares”

Propanc Biopharma, Inc.: Filed a certificate of amendment to effect a one-for-one thousand reverse stock split of common stock (effective 2023-05-01).

“On May 1, 2023, Propanc Biopharma, Inc. (the “Company”) filed a certificate of amendment (the “Certificate of Amendment”) to its certificate of incorporation, as amended (the “Certificate of Incorporation”), to effect a one-for-one thousand reverse stock split (the “Reverse Stock Split”) of its outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), effective as of May 1, 2023.”

Propanc Biopharma, Inc.: Retired Series A Preferred Stock and amended Certificate of Incorporation to eliminate all references to the series (effective 2023-03-15).

“On March 15, 2023, Propanc Biopharma, Inc. (the “Company”), filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Company’s Series A Preferred Stock (the “Series A Preferred Stock”) to eliminate from its Certificate of Incorporation, as amended (the “Certificate of Incorporation”), all references to the Series A Preferred Stock, including, without limitation, the Certificate of Designation governing the Series A Preferred Stock.”

Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $111,111 with ONE44 Capital LLC at 10% per annum maturing February 14, 2024.

“On February 14, 2023, Propanc Biopharma, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $111,111, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of ONE44.”